2-[(甲基氨基)甲基]苄醇 | 57685-24-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[(甲基氨基)甲基]苄醇
• 中文别名: 2-[(甲氨基)甲基]苯甲醇
• 英文名称: {2-[(methylamino)methyl]phenyl}methanol
• 英文别名: o-Methylaminomethyl-benzylalkohol；2-[(Methylamino)methyl]benzyl Alcohol；[2-(methylaminomethyl)phenyl]methanol
• CAS: 57685-24-2
• 化学式: C₉H₁₃NO
• mdl: MFCD09035678
• 分子量: 151.208
• InChiKey: PHVGEFLKZWWBOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  光气 、 2-[(甲基氨基)甲基]苄醇 生成 4,5-Dihydro-4-methyl-2,4-benzoxazepin-3(1H)-on
  参考文献：
  名称：

  Pifferi,G. et al., Journal of Heterocyclic Chemistry, 1972, vol. 9, p. 1209 - 1214

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基邻苯二甲酰亚胺 在 diethylzinc 、 lithium chloride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 24.0h， 以67%的产率得到2-[(甲基氨基)甲基]苄醇
  参考文献：
  名称：

  氢化硅烷化条件下轻度和选择性Et 2 Zn催化还原叔酰胺

  摘要：

  二乙基锌（Et 2 Zn）可以用作一种温和的化学选择性催化剂，在温和的反应条件下，使用经济高效的聚合硅烷（PMHS）作为氢化物源，还原叔酰胺。催化活性的关键是向反应混合物中加入亚化学计量的氯化锂。将一系列包含不同附加官能团的酰胺还原为相应的胺，并以良好至优异的产率分离出产物。

  DOI：

  10.1021/ol503430t

文献信息

• [EN] MODULATORS OF AMYLOID BETA.<br/>[FR] MODULATEURS DE LA PROTÉINE ?-AMYLOÏDE
  申请人：ASTRAZENECA AB

  公开号：WO2010053438A1

  公开（公告）日：2010-05-14

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式I的新化合物及其治疗上可接受的盐，它们的药物组合物，制造它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法的使用。特别是，本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号传导的化合物，并将用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病、唐氏综合症和β-淀粉样蛋白血管病，例如但不限于脑淀粉样血管病、遗传性脑出血、与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或包括混合血管和退行性来源的痴呆在内的疾病相关的神经退行性变、早老性痴呆、老年性痴呆和与帕金森病、进行性核上瘫或皮层基底退行性变相关的痴呆。
• 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
  申请人：Molino F. Bruce

  公开号：US20060111393A1

  公开（公告）日：2006-05-25

  The present invention relates to a method of treating disorders by administering a compound of the formulae IA-IF. These compounds are tetrahydroisoquinolines of the following structure: wherein R 1 -R 8 for compounds of each of the formulae IA, IB, IC, ID, IE and IF are as described herein.

  本发明涉及通过给予式IA-IF的化合物治疗疾病的方法。这些化合物是以下结构的四氢异喹啉：其中对于式IA、IB、IC、ID、IE和IF的化合物，R1-R8如本文所述。
• A Stable and Cleavable &lt;i&gt;O&lt;/i&gt;-Linked Spacer for Drug Delivery Systems
  作者：Kei Ito、Toshifumi Tatsumi、Kazuki Takahashi、Yohei Shimizu、Kenzo Yamatsugu、Motomu Kanai

  DOI：10.1248/cpb.c19-00376

  日期：2020.3.1

  Anti-cancer chemotherapy with good efficacy and fewer side effects is highly desirable. A drug delivery system comprising a cancer-targeting module and a cytotoxic agent connected with a cleavable linker is promising for reducing side effects. The development of a cleavable linker satisfying the requirements of both stability and cleavability, however, is difficult, especially when a carbonate moiety is used for conjugating the linker to a hydroxy group in a drug of interest. We herein report a new stable linker comprising carbamate and ester spacers, which can be introduced on a hydroxy group of a drug. This linker is more stable in aqueous neutral buffer than a corresponding carbonate-type linker, and releases a payload anti-cancer drug, SN-38, through a two-step sequence upon cathepsin B treatment. This linker may have potential use in other drug delivery systems to lower side effects by selectively transporting cytotoxic drugs to tumor cells.

  疗效好、副作用少的抗癌化疗是非常理想的。由癌症靶向模块和细胞毒剂组成的给药系统与可裂解连接剂相连接，有望减少副作用。然而，要开发出一种同时满足稳定性和可裂解性要求的可裂解连接体并不容易，尤其是在使用碳酸盐分子将连接体与相关药物中的羟基相连接的情况下。我们在此报告一种由氨基甲酸酯和酯间隔物组成的新型稳定连接体，这种连接体可被引入药物的羟基上。与相应的碳酸盐型连接体相比，这种连接体在水性中性缓冲液中更为稳定，并能在蛋白酶 B 处理后通过两步序列释放有效载荷抗癌药物 SN-38。这种连接体有可能用于其他药物输送系统，通过选择性地向肿瘤细胞输送细胞毒性药物来降低副作用。
• [EN] SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'HÉMAGGLUTININE DE LA GRIPPE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021202600A1

  公开（公告）日：2021-10-07

  Disclosed are small molecule inhibitors of influenza HA, and methods of using them to treat or prevent HA-mediated diseases and conditions.

  本发明揭示了流感HA的小分子抑制剂，以及使用它们治疗或预防HA介导的疾病和病况的方法。
• COMPOUNDS 563
  申请人：FORSBLOM Rickard

  公开号：US20100130495A1

  公开（公告）日：2010-05-27

  The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及公式I的新化合物及其治疗上可接受的盐，它们的制药组合物，制备它们的方法以及它们作为治疗和/或预防各种疾病的治疗方法。特别是本发明涉及抑制Aβ40和Aβ42产生，增加Aβ37和Aβ38产生并维持Notch信号的化合物，并将其用于治疗和/或预防与Aβ相关的病理，如阿尔茨海默病，唐氏综合症和β-淀粉样蛋白血管病，如但不限于脑淀粉样血管病，遗传性脑出血，与认知功能障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆力丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆以及与帕金森病，进行性核上性麻痹或皮层基底节变性相关的痴呆。